Importance

Loading Importance Indicators...

Abstract

A treatment method for humans infected with HTLV-III (AIDS) virus, including patients clinically diagnosed as suffering from AIDS, those suffering from AIDS-related complex (ARC) as distinguished from AIDS itself, those exhibiting a positive serum test from AIDS virus coupled with a significant measurable dimunition in immunological function, and those simply showing a positive serological test for the AIDS virus without other symptomatic indications, involves the administration, preferably orally where appropriate, of a small but effective amount in the range corresponding to about 1.0-5.0 mg per day for naltrexone, of an opiate receptor antagonist which at the indicated levels exhibits substantially antagonistic or blocking action exclusively upon Mu opiate receptors. The treatment appears from clinical data to impart substantially increased resistance against further progression of the disease beyond its original stage as well as to achieve significant symptomatic relief and clinical protection against serious further deterioration in condition in a predominant number of the patients treated, and appears further to have the ability to repair significantly existing damage to the patient's immunological system. Best results are obtained when the opiate antagonist is administered during the evening or early morning hours as contrasted with daylight or the working times, thereby enhancing the production by the body of endorphins which occurs optimally during such hours.

Loading the Abstract Image...

First Claim